Mizuho Securities Remains Bullish on Horizon Pharma (HZNP); Says Subpoena Appears Benign
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"
February 29, 2016 7:30 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 02/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today joins rare disease patient advocates worldwide in supporting the ninth annual international Rare Disease Day.
Organized annually on the last day of February by the European Organization for Rare Diseases (EURORDIS) and supported in the United... More
Horizon Pharma plc Announces Record Fourth-Quarter and Full-Year 2015 Financial Results and Confirms Full-Year 2016 Sales and Adjusted EBITDA Guidance
February 29, 2016 7:00 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 02/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its fourth-quarter and full-year 2015 financial results today and confirmed its full-year 2016 net sales and adjusted EBITDA guidance.
Financial Highlights (in millions except for per share amounts and % % percentages) Q4 15 Q4 14 Change FY 15 FY 14 Change ------- ------- ------ ------- ------- ------ Net sales $ 244.5 $ 103.8 135 $ 757.0 $ 297.0 155 Net income (loss) 24.0 (31.6) NM 39.5 (263.6) NM Adjusted non-GAAP net income 102.4 25.9 295 305.9 72.1 324 Adjusted EBITDA 122.5 34.8 252 362.1 87.1 316 Earnings (loss) per share - basic $ 0.15 $ (0.27) NM... More
